Key Takeaways
- DNA changes in blood cells can reveal whether a blood cancer is stable or progressing years before standard testing.
- Patients with stable disease often had genetically quiet MPN, while those who worsened showed emerging abnormal cell groups.
- The common drug hydroxyurea leaves a distinctive DNA pattern, but there is no evidence it causes leukemia.
- Some 'triple-negative' cases may not actually be malignant, raising questions about long-term treatment.
- Experts say the immediate value is closer monitoring, not new therapies.
DNA Clues Hidden in the Blood
A new study suggests that patterns hidden in a patient's DNA could indicate whether certain blood cancers are progressing years before routine tests catch up. The research followed 30 people with myeloproliferative neoplasms (MPNs), a group of blood cancers in which the bone marrow overproduces blood cells.
Published in Cancer Discovery by the American Association for Cancer Research, the study tracked DNA in blood and bone marrow samples over time. Researchers then compared those genetic changes with blood counts, stable disease, and progression to more serious conditions such as myelofibrosis or acute leukemia.
Stable Disease Leaves a 'Quiet' Genetic Trail
People whose disease remained stable often showed stable DNA without cancer-related genetic changes. That genetically quiet pattern suggests an MPN is more likely to stay stable. On the other hand, patients whose disease worsened frequently displayed DNA changes years before routine blood work revealed progression.
Nine participants eventually developed acute myeloid leukemia, but not all progressed the same way. In some cases, MPN cells gradually accumulated harmful mutations. In others, the leukemia appeared to arise from a separate group of abnormal blood cells. Similar differences emerged among those who developed myelofibrosis.
What This Means for Monitoring and Treatment
The researchers also identified a recognizable pattern of small DNA changes tied to hydroxyurea, a common medication used to control blood counts. Crucially, there was no evidence that the drug causes leukemia. A similar pattern was linked to azacitidine, another blood cancer drug.
Three participants had what is called triple-negative essential thrombocythemia, usually classified as a blood cancer. Yet no genetic signs of cancer appeared in their samples. That raises the possibility that some patients may not have a malignant disease at all, and may not need long-term therapy.
An Oncologist's View
Abhishek Chilkulwar, an oncologist with Orlando Health who was not involved in the study, told Fox News Digital that most people with MPNs can live with them for decades. He called the findings a striking demonstration that DNA changes may signal a blood cancer's path long before it becomes visible.
Chilkulwar said the realistic use in the near term is modest: closer monitoring, not new treatment. A patient with a high-risk mutation could be shifted to more frequent blood counts and, if needed, more frequent bone marrow checks. But he cautioned that the results should not drive patients toward aggressive measures like transplant before actual progression occurs.
The next step, he said, would be pairing early genetic detection with drugs that target specific mutations, potentially preventing or delaying progression altogether.
Why This Matters
This research moves blood cancer care closer to true precision medicine, where a patient's own DNA could predict risk years in advance. While the tools to act on those predictions are still being built, the potential to intervene before disease progresses could reshape how these cancers are monitored and treated.